Exploring a Novel Mechanism of Action With the Development of TCR-PD1 Agonist Bispecifics For The Treatment of Autoimmune Diseases
- Aiming to deliver tissue-specific TCR-based therapeutics
- Adapting the ImmTAC platform with a novel effector function to address autoimmune diseases
- Exploring the Development of a beta-cell targeted Immune Suppressive PD-1 Agonist Bispecific to treat type I diabetes